STOCKHOLM--(BUSINESS WIRE)--SciBase, a Swedish medical technology company that has developed a unique point-of-care device for the accurate detection of malignant melanoma, today announces the establishment of a Scientific Advisory Board. The Board, which is composed of world-leading dermatology experts, will advise SciBase as they develop the company.
SciBase’s Scientific Advisory Board has already held its first meeting and the Board’s main function will be to advise the company on how to improve and increase acceptance of the method and the product, Nevisense. Additionally, the Board will assist in the development of the next generation of Nevisense and provide guidance in regards to upcoming clinical studies.
The board is composed of five world-leading physicians:
- Dr Allan C. Halpern
Chief of Dermatology Service at Memorial Sloan-Kettering Cancer Center in New York
- Dr David E. Elder
Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania
- Dr Scott W. Menzies
Professor of Medicine, Discipline of Dermatology and Director of Sydney Melanoma Diagnostic Centre
- Dr Josep Malvehy
Director of the Melanoma Unit at University Hospital Clinic of Barcelona
- Dr Holger Hänßle
Senior Physician at Heidelberg University Clinic
IPO on Nasdaq OMX First North in June
On April 23 SciBase announced its upcoming IPO and listing on Nasdaq First North in June 2015. The main purpose of the IPO is to finance Scibase’s continued expansion and commercialization, which is the company focus for 2015. Further announcements relating to the Initial Public Offering will be made in due course.
“With the development of our product Nevisense now completed, our focus is on building a solid base for the future. Our Scientific Advisory Board’s leading expertise and experience will be invaluable in driving our product and company forward and we are excited to have their support. With our IPO, we will raise the capital needed to expand sales and marketing of Nevisense. Nevisense is contributing to a safer and more effective detection of skin cancer, which benefits both health care systems and patients”, says Simon Grant, CEO at SciBase.
About SciBase and Nevisense
SciBase is a Swedish medical technology company founded in 1998 that has developed Nevisense, a point-of-care device for the accurate detection of malignant melanoma. Nevisense has emerged from more than 20 years of research at Karolinska Institute in Stockholm and at SciBase. The device is designed to be provide additional information when evaluating lesions with a suspicion of melanoma. Nevisense is based on a technology called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. The CE-marked system consists of an electrode on a hand-held probe connected to a small portable device performing the analysis and displaying the result.
Further is available on www.scibase.com.
This information was brought to you by Cision http://news.cision.com